Document is current
Any future updates will be listed below
-
Authors
Kondoh, Yasuhiro
Furukawa, Taiki
Hozumi, Hironao
Suda, Takafumi
Egashira, Ryoko
Jokoh, Takeshi
Fukuoka, Junya
Kuwana, Masataka
Teramachi, Ryo
Fujisawa, Tomoyuki
Hasegawa, Yoshinori
Ogura, Takashi
Miyazaki, Yasunari
Oyama, Shintaro
Teramukai, Satoshi
Horiguchi, Go
Naito, Akari
Inoue, Yoshikazu
Ichikado, Kazuya
Bando, Masashi
Tomioka, Hiromi
Nishioka, Yasuhiko
Chiba, Hirofumi
Ebina, Masahito
Nakanishi, Yoichi
Satoh, Kikue
Shiratori, Yoshimune
Hashimoto, Naozumi
Ishii, Makoto
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim Japan
JSPS KAKENHI (JP19110253)
The Hori Science and Arts Foundation
the Japanese Respiratory Foundation
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 19 August 2024
First Online: 14 October 2024
Declarations
:
: This study was approved by the Nagoya University Ethics Committee and the Ethics Committee of each participating institution. All enrolled patients provided written informed consent prior to enrolment in the study. This study was registered with the UMIN Clinical Trials Registry (, UMIN000040678) on July 1, 2020.
: Not applicable.
: YK reports personal fees from Asahi Kasei Pharma Corp.; Boehringer Ingelheim Co., Ltd.; Eisai Inc.; KYORIN Pharmaceutical Co., Ltd.; Novartis Pharma K.K.; and Shionogi & Co. outside of the submitted work. KS reports grants from the Pulmonary Fibrosis Foundation and Novartis Pharma outside the submitted work. JF holds stocks in PathPresenter and serves on an advisory board at N Lab Co., Ltd. MI reports advisory board participation and lecture fees from GlaxoSmithKline plc. and Moderna Japan Co., Ltd., and lecture fees from Shionogi & Co., Ltd., AstraZeneca K.K., KYORIN Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., MSD K.K., Insmed, Inc., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Abbott Diagnostics Medical Co., Ltd., TAIHO PHARMACEUTICAL Co., LTD., Amgen K.K., and Novartis Pharma K.K., outside the submitted work. All other authors report no competing interests.
